Fri Sep 20 12:16:13 UTC 2024: ## Cytokinetics (CYTK) Stock Reaffirmed as “Buy” by HC Wainwright

**New York, NY – September 20, 2024** – Research analysts at HC Wainwright have reiterated their “buy” rating for Cytokinetics (NASDAQ:CYTK) and set a price target of $90.00, representing a potential upside of 61.87% from the company’s previous close.

The biopharmaceutical company has seen a mixed bag of analyst opinions in recent months. While Cantor Fitzgerald and JPMorgan Chase & Co. have issued “overweight” ratings, B. Riley downgraded their price target to $92.00, and Bank of America lowered theirs to $60.00, maintaining a “neutral” rating. Overall, Cytokinetics has a consensus rating of “Moderate Buy” and a consensus price target of $80.67.

Cytokinetics recently reported earnings results for the quarter ending August 8th, missing analyst expectations for earnings per share but exceeding revenue forecasts. The company’s revenue saw a significant decline year-over-year, but analysts are optimistic about the company’s future performance, forecasting a -5.15 EPS for the current fiscal year.

Recent insider trading activity shows EVP Fady Ibraham Malik sold 7,300 shares on June 25th, followed by CEO Robert I. Blum selling 11,500 shares on July 1st. Over the past 90 days, insiders have sold a total of 107,837 shares of company stock.

Large investors have also been active in the stock, with Vanguard Personalized Indexing Management LLC, Norges Bank, TD Asset Management Inc, Crestline Management LP, and NEOS Investment Management LLC all making significant purchases during the 4th quarter.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company focused on developing potential treatments for debilitating diseases through the use of muscle activators and inhibitors. The company’s current focus is on small molecule drug candidates designed to impact muscle function and contractility.

Read More